Araxes Pharma LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Substituted Quinazoline Compounds and Methods of Use Thereof (US 10,351,550) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 2 fees due Feb 6 to 13, 2027 · next Feb 6
- 1 fee due Mar 17, 2027The maintenance fee for 2-Substituted Quinazoline Compounds Comprising a Substituted Heterocyclic Group and Methods of Use Thereof (US 10,414,757) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Apr 1, 2027The maintenance fee for Fused-tricyclic inhibitors of KRAS and methods of use thereof (US 10,428,064) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
- 2 fees due Jul 5 to 23, 2027 · next Jul 5
- 2 fees due Nov 12, 2027
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,227,978 | Covalent Inhibitors of Kras G12C In force · High confidence | In force | High confidence | |
| US 9,926,267 | Covalent Inhibitors of Kras G12C In force · High confidence | In force | High confidence | |
| US 10,273,207 | Covalent Inhibitors of Kras G12C In force · High confidence | In force | High confidence | |
| US RE50,527 | Covalent Inhibitors of Kras G12C In force · Low confidence | In force | Low confidence | |
| US 9,840,516 | Substituted Quinazolines as Inhibitors of Kras G12C In force · High confidence | In force | High confidence | |
| US 10,111,874 | Combination Therapies for Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 10,144,724 | Substituted Quinazoline Compounds and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,351,550 | Substituted Quinazoline Compounds and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 10,370,386 | Substituted Quinolines as Inhibitors of Kras G12C In force · Medium confidence | In force | Medium confidence | |
| US 10,927,125 | Substituted Cinnolines as Inhibitors of Kras G12C In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 36: 8 lapsed for an unpaid fee · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 5 abandoned · 5 no status recorded